



Institute and Faculty of Actuaries

## The Lost Generation... overstated (??) mortality improvements for younger lives

Matthew Smith: Head of Global Research, Pacific Life Re

16 May 2016

---

---

---

---

---

---

---

---

---

---

### Aims of this presentation

<b>Materiality</b>	How important are mortality improvement assumptions for pricing and valuation?
<b>Modelling</b>	What models are suitable for younger lives and what do existing models tell us?
<b>Recent Trends</b>	What does the historic data show and what is driving the recent trends?
<b>Basis Risk</b>	How can we determine a reasonable basis for insured lives?

16 May 2016 2

---

---

---

---

---

---

---


---

---

---

### Some Background

- Life cover premium rates have tumbled



Approximate Term Assurance Rates as % of 2004 Rates

Calendar Year	Approximate Term Assurance Rates as % of 2004 Rates
2004	100%
2005	95%
2006	90%
2007	85%
2008	80%
2009	78%
2010	75%
2011	78%
2012	78%
2013	80%
2014	75%
2015	70%

Term assurance rates have dropped materially in recent years

16 May 2016 3

---

---

---

---

---

---

---


---

---

---

## Some background...

- It is clear that we are living longer



16 May 2016

4

---

---

---

---

---

---

---

---

---

---

---

---

## Setting an improvement basis

- Mortality risk gets less attention than longevity

### A Brief History Lesson...

SIAS paper "A Term Life"	2000	Suggested that improvements of 0.75%-1% for males and 0%-0.25% for females would be suitable for Term Assurance business
CMIR17 & working paper 1	1999-2002	Original CMI mortality improvements associated with the '92 series' of tables & the historically ubiquitous 'interim' cohort projections.
CMI working Papers 3, 15, 20, 25	2005-2007	CMI begin to explore Lee-Carter and P-Spline stochastic projection methodologies
CMI Model (WPs 38, 39, 41, 49, 54, 55, 64, 69, 79, 80, 84)	2009-2015	Move away from a stochastic methodology and develop a deterministic projection model (CMI_2015 is latest).

*"The purpose of the CMI Mortality Projections Model is to allow users to produce projections of annual rates of mortality improvement, in particular in the context of UK pension and annuity portfolios". CMI\_2015 User Guide*

**But what about younger, insured lives?**

16 May 2016

5

---

---

---

---

---

---

---

---

---

---

---

---

## Setting an improvement basis

- How much credit has been given for insured lives in the industry?

There does not appear to be much of a consensus for insured lives...

But it is important...

(particularly given today's margins)

It is likely that insurers (or reinsurers) have gradually been giving more credit for higher improvement rates

16 May 2016

6

---

---

---

---

---

---

---

---

---

---

---

---

# Financial Sensitivity

## - Defining a dummy term assurance portfolio

### New business mix

		Term						
		5	10	15	20	25	30	35
Age at Entry	20	-	-	-	-	1%	-	-
	25	-	-	-	1%	3%	2%	2%
	30	-	-	1%	2%	5%	3%	1%
	35	1%	1%	2%	5%	8%	2%	-
	40	1%	2%	3%	7%	7%	1%	-
	45	1%	3%	5%	7%	2%	-	-
	50	1%	3%	5%	2%	-	-	-
55	1%	3%	2%	-	-	-	-	
60	1%	1%	-	-	-	-	-	

Sex	Smoker	
	N	Y
Male	45%	10%
Female	35%	10%

Benefit Level	Total
Decreasing	50%
Level	50%

### Assumptions

- 100% TMFNS00 as at 2000
- 1% per annum improvements from 2000 to 2015
- 2.5% discount rate
- 6% mortgage interest rate for DTA
- £1bn of sum assured sold in 2012
- Base case: Future improvements 2016+ of 0.5% per annum
- Sensitivity: Future improvements 2016+ of 1.5% per annum

---

---

---

---

---

---


---

---

# Financial Sensitivity

## - Increasing improvement rates by 1%

Projected Claims for our Dummy Portfolio



Basis	PV Claims	% Impact
0.5% improvements	£8.5m	-
1.5% improvements	£7.7m	-9.2%

Obviously a key assumption

---

---

---

---

---

---


---

---

# Financial Sensitivity

## - Next, let's move to the CMI\_2015 model

### Overview of Model



For simplicity, let's simply retain the default assumptions and choose a long-term rate of 1.5%

### Do we have any expectations

In words: we are giving full credit for "longevity style" improvement rates  
Will our liabilities decrease?

---

---

---




---

---

---

---


---



### Financial Sensitivity

- What is driving this?

The convergence can be shown in heat map form:



16 May 2016

13

---

---

---

---

---

---

---

---

---

---

---


---

### Exploring this further

A more detailed look at recent trends

$$\mu_{x,t} = \frac{\text{deaths}_{x,t}}{\text{population}_{x,t}}$$

$$\text{improv}_{x,t} = 1 - \frac{\mu_{x,t}}{\mu_{x,t-1}}$$



16 May 2016

14

---

---

---

---

---

---

---

---

---

---


---

---

### Exploring this further

A detailed look at recent trends

➤ We can clearly see cohort and period effects



16 May 2016

15

---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

---

---

### Recent Year of Birth Cohort Effects

The key questions...

**Cause**

What are the drivers of the more recent cohort effects?  
 Inevitable post golden cohort hangover?  
*Obesity? Diabetes? Alcohol? AIDS?*

---

**Relevance**

Are they relevant for insured lives?  
 - Does underwriting help?  
 - Are they related to socio-economic class?

---

**Persistence**

Will they persist?  
 - Is there age dependence?  
 - Is there time dependence?

16 May 2016 17

---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

---

---

### Recent Year of Birth Cohort Effects AIDS Deaths

*Proportion of male deaths associated with HIV/AIDS*

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
1-4	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
5-9	1%	2%	1%	2%	0%	1%	1%	0%	0%	0%	0%	0%	0%	0%	0%	1%	0%	0%
10-14	2%	0%	2%	1%	0%	0%	0%	0%	0%	1%	1%	1%	0%	1%	0%	1%	0%	2%
15-19	0%	0%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	1%	0%	0%	0%
20-24	1%	3%	1%	1%	0%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	1%
25-29	7%	7%	6%	6%	3%	2%	1%	2%	2%	1%	1%	1%	2%	2%	1%	1%	1%	0%
30-34	10%	10%	10%	11%	0%	3%	2%	2%	2%	2%	2%	2%	3%	3%	2%	2%	1%	2%
35-39	11%	12%	12%	11%	5%	5%	3%	3%	2%	4%	3%	2%	3%	2%	3%	3%	2%	2%
40-44	6%	6%	7%	7%	3%	2%	2%	2%	2%	2%	2%	3%	3%	2%	2%	3%	2%	3%
45-49	3%	4%	3%	3%	2%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	2%
50-54	1%	1%	1%	1%	0%	0%	0%	0%	0%	0%	1%	0%	0%	1%	1%	1%	1%	1%
55-59	0%	1%	1%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	1%
60-64	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
65-69	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
70-74	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
75-79	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
80-84	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
85+	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Source: ONS & Health Protection Agency Data

16 May 2016 21

---

---

---

---

---

---

---

---

---

---

---

---

### Recent Year of Birth Cohort Effects Relevance for Insured Lives


*Is this poor cohort of lives relevant for insured products?*

**No!**

Underwriting is protective

Many of these trends may not be relevant for higher socio-economic classes

AIDS has now been managed successfully



**Yes!**

Not protective against weight gain

We only apply ratings at certain cut-off BMI levels

Trends by socio-economic class can work both ways

16 May 2016 22

---

---

---

---

---

---

---

---


---

---

### Recent Year of Birth Cohort Effects Relevance for Insured Lives

$$\log \mu(x, t) = a(x) + k(t) + \gamma(t - x)$$

**Fitted Gamma(t-x)**



16 May 2016 23

---

---

---

---

---

---

---


---

---


---

### Recent Year of Birth Cohort Effects Relevance for Insured Lives

*England & Wales Population*



*CMI Assured Lives*



16 May 2016 24

---

---

---

---

---

---

---

---

---

---



### The Impact of Smoking Cessation

Relevance for Insured Lives

<b>Problem</b>	We rate for smoking status but... Much of the historic improvements are associated with giving up
<b>Data</b>	Population data is not segregated by smoking status
<b>Possible Solution</b>	Develop a multi-state prevalence model and project separately for smokers and non-smokers
<b>Impact</b>	Ignoring movements in smoking prevalence will over-estimate mortality improvements

16 May 2016 25

---

---

---

---

---

---

---

---

---

---

### Conclusions

<b>Importance</b>	This is a key assumption for term assurance business
<b>Financial impact</b>	It is not obvious that "longevity style" models will give lower liabilities
<b>Cohort vs Period</b>	Beware of models that don't consider cohort effects
<b>Smoking</b>	For insured lives we cannot give (much) credit for giving up smoking
<b>Recent cohort effects</b>	The extent to which these will persist is of course unknown
<b>Basis Risk</b>	Trends inferred from the population should be considered carefully

16 May 2016 26

---

---

---

---

---

---

---

---

---

---

## Questions

## Comments

The views expressed in this [publication/presentation] are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this [publication/presentation] and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this [publication/presentation].

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this [publication/presentation] be reproduced without the written permission of the IFoA [or authors, in the case of non-IFoA research].

16 May 2016 27

---

---

---

---

---

---

---

---

---

---